Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.
Identifieur interne : 001379 ( PubMed/Checkpoint ); précédent : 001378; suivant : 001380Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.
Auteurs : Xiang Qiu [République populaire de Chine] ; Chao Hong ; Yue Li ; Wanrong Bao ; Xiao-Ming GaoSource :
- Microbiology and immunology [ 1348-0421 ] ; 2012.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Adjuvants immunologiques (génétique), Animaux, Anticorps antiviraux (sang), Calréticuline (administration et posologie), Calréticuline (génétique), Femelle, Glycoprotéine de spicule des coronavirus, Glycoprotéines membranaires (immunologie), Immunoglobuline G (sang), Injections sous-cutanées, Protéines de fusion recombinantes (génétique), Protéines de fusion recombinantes (immunologie), Protéines de l'enveloppe virale (immunologie), Souris, Souris de lignée BALB C, Souris nude, Vaccins antiviraux (administration et posologie), Vaccins antiviraux (immunologie), Vaccins synthétiques (administration et posologie), Vaccins synthétiques (immunologie), Virus du SRAS (immunologie).
- MESH :
- administration et posologie : Adjuvants immunologiques, Calréticuline, Vaccins antiviraux, Vaccins synthétiques.
- génétique : Adjuvants immunologiques, Calréticuline, Protéines de fusion recombinantes.
- immunologie : Glycoprotéines membranaires, Protéines de fusion recombinantes, Protéines de l'enveloppe virale, Vaccins antiviraux, Vaccins synthétiques, Virus du SRAS.
- sang : Anticorps antiviraux, Immunoglobuline G.
- Animaux, Femelle, Glycoprotéine de spicule des coronavirus, Injections sous-cutanées, Souris, Souris de lignée BALB C, Souris nude.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adjuvants, Immunologic (genetics), Animals, Antibodies, Viral (blood), Calreticulin (administration & dosage), Calreticulin (genetics), Female, Immunoglobulin G (blood), Injections, Subcutaneous, Membrane Glycoproteins (immunology), Mice, Mice, Inbred BALB C, Mice, Nude, Recombinant Fusion Proteins (genetics), Recombinant Fusion Proteins (immunology), SARS Virus (immunology), Spike Glycoprotein, Coronavirus, Vaccines, Synthetic (administration & dosage), Vaccines, Synthetic (immunology), Viral Envelope Proteins (immunology), Viral Vaccines (administration & dosage), Viral Vaccines (immunology).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Calreticulin, Vaccines, Synthetic, Viral Vaccines.
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , genetics : Adjuvants, Immunologic, Calreticulin, Recombinant Fusion Proteins.
- chemical , immunology : Membrane Glycoproteins, Recombinant Fusion Proteins, Vaccines, Synthetic, Viral Envelope Proteins, Viral Vaccines.
- immunology : SARS Virus.
- Animals, Female, Injections, Subcutaneous, Mice, Mice, Inbred BALB C, Mice, Nude, Spike Glycoprotein, Coronavirus.
Abstract
Fragment 450-650 of the spike (S) protein (S450-650) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) contains epitopes capable of being recognized by convalescent sera of SARS patients. Vaccination of mice with recombinant S450-650 (rS450-650) can induce Abs against SARS-CoV, although the titer is relatively low. In the present study, a fusion protein linking a fragment (residues 39-272) of murine calreticulin (CRT) to S450-650 in a prokaryotic expression system was created. Compared with target antigen alone, the recombinant fusion product (rS450-650-CRT) has much improved hydrophilicity and immunogenicity. The S450-650-specific IgG Abs of BALB/c mice subcutaneously immunized with rS450-650-CRT were in substantially higher titer (approximately fivefold more). Furthermore, the fusion protein, but not rS450-650 alone, was able to elicit S450-650-specific IgG responses in T cell deficient nude mice. Given that rCRT/39-272 can drive the maturation of bone-marrow-derived dendritic cells, directly activate macrophages and B cells, and also elicit helper T cell responses in vivo, we propose that fragment 39-272 of CRT is an effective molecular adjuvant capable of enhancing target Ag-specific humoral responses in both a T cell-dependent and independent manner. Fusion protein rS450-650-CRT is a potential candidate vaccine against SARS-CoV infection.
DOI: 10.1111/j.1348-0421.2012.00467.x
PubMed: 22530918
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:22530918Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.</title>
<author><name sortKey="Qiu, Xiang" sort="Qiu, Xiang" uniqKey="Qiu X" first="Xiang" last="Qiu">Xiang Qiu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Peking University Health Science Center, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Immunology, Peking University Health Science Center, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hong, Chao" sort="Hong, Chao" uniqKey="Hong C" first="Chao" last="Hong">Chao Hong</name>
</author>
<author><name sortKey="Li, Yue" sort="Li, Yue" uniqKey="Li Y" first="Yue" last="Li">Yue Li</name>
</author>
<author><name sortKey="Bao, Wanrong" sort="Bao, Wanrong" uniqKey="Bao W" first="Wanrong" last="Bao">Wanrong Bao</name>
</author>
<author><name sortKey="Gao, Xiao Ming" sort="Gao, Xiao Ming" uniqKey="Gao X" first="Xiao-Ming" last="Gao">Xiao-Ming Gao</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22530918</idno>
<idno type="pmid">22530918</idno>
<idno type="doi">10.1111/j.1348-0421.2012.00467.x</idno>
<idno type="wicri:Area/PubMed/Corpus">001374</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001374</idno>
<idno type="wicri:Area/PubMed/Curation">001374</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001374</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001379</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001379</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.</title>
<author><name sortKey="Qiu, Xiang" sort="Qiu, Xiang" uniqKey="Qiu X" first="Xiang" last="Qiu">Xiang Qiu</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Immunology, Peking University Health Science Center, Beijing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Immunology, Peking University Health Science Center, Beijing</wicri:regionArea>
<placeName><settlement type="city">Pékin</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hong, Chao" sort="Hong, Chao" uniqKey="Hong C" first="Chao" last="Hong">Chao Hong</name>
</author>
<author><name sortKey="Li, Yue" sort="Li, Yue" uniqKey="Li Y" first="Yue" last="Li">Yue Li</name>
</author>
<author><name sortKey="Bao, Wanrong" sort="Bao, Wanrong" uniqKey="Bao W" first="Wanrong" last="Bao">Wanrong Bao</name>
</author>
<author><name sortKey="Gao, Xiao Ming" sort="Gao, Xiao Ming" uniqKey="Gao X" first="Xiao-Ming" last="Gao">Xiao-Ming Gao</name>
</author>
</analytic>
<series><title level="j">Microbiology and immunology</title>
<idno type="eISSN">1348-0421</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term>
<term>Adjuvants, Immunologic (genetics)</term>
<term>Animals</term>
<term>Antibodies, Viral (blood)</term>
<term>Calreticulin (administration & dosage)</term>
<term>Calreticulin (genetics)</term>
<term>Female</term>
<term>Immunoglobulin G (blood)</term>
<term>Injections, Subcutaneous</term>
<term>Membrane Glycoproteins (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Recombinant Fusion Proteins (genetics)</term>
<term>Recombinant Fusion Proteins (immunology)</term>
<term>SARS Virus (immunology)</term>
<term>Spike Glycoprotein, Coronavirus</term>
<term>Vaccines, Synthetic (administration & dosage)</term>
<term>Vaccines, Synthetic (immunology)</term>
<term>Viral Envelope Proteins (immunology)</term>
<term>Viral Vaccines (administration & dosage)</term>
<term>Viral Vaccines (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term>
<term>Adjuvants immunologiques (génétique)</term>
<term>Animaux</term>
<term>Anticorps antiviraux (sang)</term>
<term>Calréticuline (administration et posologie)</term>
<term>Calréticuline (génétique)</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Glycoprotéines membranaires (immunologie)</term>
<term>Immunoglobuline G (sang)</term>
<term>Injections sous-cutanées</term>
<term>Protéines de fusion recombinantes (génétique)</term>
<term>Protéines de fusion recombinantes (immunologie)</term>
<term>Protéines de l'enveloppe virale (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris nude</term>
<term>Vaccins antiviraux (administration et posologie)</term>
<term>Vaccins antiviraux (immunologie)</term>
<term>Vaccins synthétiques (administration et posologie)</term>
<term>Vaccins synthétiques (immunologie)</term>
<term>Virus du SRAS (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Calreticulin</term>
<term>Vaccines, Synthetic</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term>
<term>Immunoglobulin G</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Adjuvants, Immunologic</term>
<term>Calreticulin</term>
<term>Recombinant Fusion Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Membrane Glycoproteins</term>
<term>Recombinant Fusion Proteins</term>
<term>Vaccines, Synthetic</term>
<term>Viral Envelope Proteins</term>
<term>Viral Vaccines</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Calréticuline</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Adjuvants immunologiques</term>
<term>Calréticuline</term>
<term>Protéines de fusion recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Glycoprotéines membranaires</term>
<term>Protéines de fusion recombinantes</term>
<term>Protéines de l'enveloppe virale</term>
<term>Vaccins antiviraux</term>
<term>Vaccins synthétiques</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term>
<term>Immunoglobuline G</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Injections, Subcutaneous</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Mice, Nude</term>
<term>Spike Glycoprotein, Coronavirus</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Femelle</term>
<term>Glycoprotéine de spicule des coronavirus</term>
<term>Injections sous-cutanées</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Souris nude</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Fragment 450-650 of the spike (S) protein (S450-650) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) contains epitopes capable of being recognized by convalescent sera of SARS patients. Vaccination of mice with recombinant S450-650 (rS450-650) can induce Abs against SARS-CoV, although the titer is relatively low. In the present study, a fusion protein linking a fragment (residues 39-272) of murine calreticulin (CRT) to S450-650 in a prokaryotic expression system was created. Compared with target antigen alone, the recombinant fusion product (rS450-650-CRT) has much improved hydrophilicity and immunogenicity. The S450-650-specific IgG Abs of BALB/c mice subcutaneously immunized with rS450-650-CRT were in substantially higher titer (approximately fivefold more). Furthermore, the fusion protein, but not rS450-650 alone, was able to elicit S450-650-specific IgG responses in T cell deficient nude mice. Given that rCRT/39-272 can drive the maturation of bone-marrow-derived dendritic cells, directly activate macrophages and B cells, and also elicit helper T cell responses in vivo, we propose that fragment 39-272 of CRT is an effective molecular adjuvant capable of enhancing target Ag-specific humoral responses in both a T cell-dependent and independent manner. Fusion protein rS450-650-CRT is a potential candidate vaccine against SARS-CoV infection.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22530918</PMID>
<DateCompleted><Year>2012</Year>
<Month>11</Month>
<Day>28</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>15</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1348-0421</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>56</Volume>
<Issue>8</Issue>
<PubDate><Year>2012</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Microbiology and immunology</Title>
<ISOAbbreviation>Microbiol. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus.</ArticleTitle>
<Pagination><MedlinePgn>554-61</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1348-0421.2012.00467.x</ELocationID>
<Abstract><AbstractText>Fragment 450-650 of the spike (S) protein (S450-650) of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) contains epitopes capable of being recognized by convalescent sera of SARS patients. Vaccination of mice with recombinant S450-650 (rS450-650) can induce Abs against SARS-CoV, although the titer is relatively low. In the present study, a fusion protein linking a fragment (residues 39-272) of murine calreticulin (CRT) to S450-650 in a prokaryotic expression system was created. Compared with target antigen alone, the recombinant fusion product (rS450-650-CRT) has much improved hydrophilicity and immunogenicity. The S450-650-specific IgG Abs of BALB/c mice subcutaneously immunized with rS450-650-CRT were in substantially higher titer (approximately fivefold more). Furthermore, the fusion protein, but not rS450-650 alone, was able to elicit S450-650-specific IgG responses in T cell deficient nude mice. Given that rCRT/39-272 can drive the maturation of bone-marrow-derived dendritic cells, directly activate macrophages and B cells, and also elicit helper T cell responses in vivo, we propose that fragment 39-272 of CRT is an effective molecular adjuvant capable of enhancing target Ag-specific humoral responses in both a T cell-dependent and independent manner. Fusion protein rS450-650-CRT is a potential candidate vaccine against SARS-CoV infection.</AbstractText>
<CopyrightInformation>© 2012 The Societies and Blackwell Publishing Asia Pty Ltd.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qiu</LastName>
<ForeName>Xiang</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Immunology, Peking University Health Science Center, Beijing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hong</LastName>
<ForeName>Chao</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Li</LastName>
<ForeName>Yue</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Bao</LastName>
<ForeName>Wanrong</ForeName>
<Initials>W</Initials>
</Author>
<Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Xiao-Ming</ForeName>
<Initials>XM</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Australia</Country>
<MedlineTA>Microbiol Immunol</MedlineTA>
<NlmUniqueID>7703966</NlmUniqueID>
<ISSNLinking>0385-5600</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D037282">Calreticulin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578553">MHV surface projection glycoprotein</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008562">Membrane Glycoproteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011993">Recombinant Fusion Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014759">Viral Envelope Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014765">Viral Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C578557">spike glycoprotein, SARS-CoV</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D037282" MajorTopicYN="N">Calreticulin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007279" MajorTopicYN="N">Injections, Subcutaneous</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008562" MajorTopicYN="N">Membrane Glycoproteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008819" MajorTopicYN="N">Mice, Nude</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011993" MajorTopicYN="N">Recombinant Fusion Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D064370" MajorTopicYN="N">Spike Glycoprotein, Coronavirus</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014759" MajorTopicYN="N">Viral Envelope Proteins</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014765" MajorTopicYN="N">Viral Vaccines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2012</Year>
<Month>4</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>12</Month>
<Day>10</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22530918</ArticleId>
<ArticleId IdType="doi">10.1111/j.1348-0421.2012.00467.x</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>République populaire de Chine</li>
</country>
<settlement><li>Pékin</li>
</settlement>
</list>
<tree><noCountry><name sortKey="Bao, Wanrong" sort="Bao, Wanrong" uniqKey="Bao W" first="Wanrong" last="Bao">Wanrong Bao</name>
<name sortKey="Gao, Xiao Ming" sort="Gao, Xiao Ming" uniqKey="Gao X" first="Xiao-Ming" last="Gao">Xiao-Ming Gao</name>
<name sortKey="Hong, Chao" sort="Hong, Chao" uniqKey="Hong C" first="Chao" last="Hong">Chao Hong</name>
<name sortKey="Li, Yue" sort="Li, Yue" uniqKey="Li Y" first="Yue" last="Li">Yue Li</name>
</noCountry>
<country name="République populaire de Chine"><noRegion><name sortKey="Qiu, Xiang" sort="Qiu, Xiang" uniqKey="Qiu X" first="Xiang" last="Qiu">Xiang Qiu</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001379 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 001379 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:22530918 |texte= Calreticulin as a hydrophilic chimeric molecular adjuvant enhances IgG responses to the spike protein of severe acute respiratory syndrome coronavirus. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:22530918" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |